CARB-X FUNDS UNIVERSITY OF QUEENSLAND TO ACCELERATE THE DEVELOPMENT OF A NEW CLASS OF LAST-RESORT ANTIBIOTICS TO TREAT DEADLY SUPERBUG INFECTIONS

  24 June 2020

CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience, Brisbane, Australia, to develop a new class of antibiotics to treat serious drug-resistant bacterial infections. The Institute will be eligible for an additional $7.03 million if the project meets certain development milestones, for a total award of up to $10.86 million.

The University of Queensland’s project aims to identify Octapeptin cyclic peptides that maintain their antibacterial potency against polymyxin-resistant Gram-negative pathogens, but have fewer side effects.  The goal is to develop a safer antibiotic to replace last-resort polymyxin class antibiotics, such as colistin, that are used to treat life-threatening drug-resistant infections for which no other antibiotics will work. Last-resort polymyxin class antibiotics can cause severe kidney and neurological side effects.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!